{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:58:32Z","timestamp":1785484712404,"version":"3.56.0"},"reference-count":110,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Med."],"abstract":"<jats:p>Metastatic castration-resistant prostate cancer (mCRPC) is associated with poor prognosis. Currently, treatment selection and response assessment in mCRPC still rely largely on prostate-specific antigen (PSA) and imaging tools, which may be insensitive and biologically noninformative. Liquid biopsy (LB), particularly circulating tumor DNA (ctDNA), offers a minimally invasive and reproducible approach for real-time assessment of tumor burden and tumor genomics. Across major treatment classes, ctDNA tumor fraction has shown consistent prognostic value, while selected genomic alterations may provide therapy-specific predictive information. Early on-treatment ctDNA kinetics are also emerging as dynamic markers of response, although prospective validation is required before routine clinical implementation. In this narrative review, we synthesize current evidence on ctDNA biology, detection methods, and its clinical utility across key mCRPC treatment classes, including androgen receptor pathway inhibitors (ARPIs), taxane chemotherapy, PARP inhibitors, and PSMA-targeted radioligand therapy (RLT). We critically examine ctDNA tumor fraction as a pan-therapy prognostic biomarker, genomic alterations as potential predictors of treatment sensitivity or resistance, early kinetic changes as surrogate markers of response, and the biological and technical limitations that currently restrict clinical adoption. Overall, the current evidence base for ctDNA in mCRPC remains predominantly prognostic rather than definitively predictive. Its integration into routine clinical practice will require prospective biomarker-driven trials, assay standardization, and a clear demonstration of clinical utility. At present, ctDNA is best positioned as a complementary tool for risk stratification and disease monitoring, with the potential to evolve into a clinically actionable biomarker for treatment decision-making.<\/jats:p>","DOI":"10.3389\/fmmed.2026.1852641","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:13:17Z","timestamp":1785481997000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating tumour DNA in mCRPC: bridging tumour biology and real-time treatment monitoring"],"prefix":"10.3389","volume":"6","author":[{"given":"Chimbabantu","family":"Kaoma","sequence":"first","affiliation":[{"name":"Department of Basic & Translational Research, Nuclear Medicine Research Infrastructure (NuMeRI)","place":["Pretoria, South Africa"]},{"name":"Department of Nuclear Medicine, University of Pretoria (UP) & Steve Biko Academic Hospital","place":["Pretoria, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Sathekge","sequence":"additional","affiliation":[{"name":"Department of Basic & Translational Research, Nuclear Medicine Research Infrastructure (NuMeRI)","place":["Pretoria, South Africa"]},{"name":"Department of Nuclear Medicine, University of Pretoria (UP) & Steve Biko Academic Hospital","place":["Pretoria, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Chalwe","sequence":"additional","affiliation":[{"name":"Department of Basic & Translational Research, Nuclear Medicine Research Infrastructure (NuMeRI)","place":["Pretoria, South Africa"]},{"name":"Department of Nuclear Medicine, University of Pretoria (UP) & Steve Biko Academic Hospital","place":["Pretoria, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kgomotso","family":"Mokoala","sequence":"additional","affiliation":[{"name":"Department of Basic & Translational Research, Nuclear Medicine Research Infrastructure (NuMeRI)","place":["Pretoria, South Africa"]},{"name":"Department of Nuclear Medicine, University of Pretoria (UP) & Steve Biko Academic Hospital","place":["Pretoria, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mankgopo","family":"Kgatle","sequence":"additional","affiliation":[{"name":"Department of Basic & Translational Research, Nuclear Medicine Research Infrastructure (NuMeRI)","place":["Pretoria, South Africa"]},{"name":"Department of Nuclear Medicine, University of Pretoria (UP) & Steve Biko Academic Hospital","place":["Pretoria, South Africa"]},{"name":"Department of Medicine, University of Cape Town and Groote Schuur Hospital","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9262","DOI":"10.3390\/curroncol30100669","article-title":"A meta-analysis of randomized clinical trials assessing the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer","volume":"30","author":"Alameddine","year":"2023","journal-title":"Curr. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","article-title":"Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study","volume":"84","author":"Abida","year":"2023","journal-title":"Eur. Urol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","volume":"8","author":"Annala","year":"2018","journal-title":"Cancer Discov."},{"key":"B4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/pcan.2016.17","article-title":"Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting","volume":"19","author":"Antonarakis","year":"2016","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","article-title":"Prostate cancer","volume":"387","author":"Attard","year":"2016","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1200\/JCO.2024.42.16_suppl.5020","article-title":"Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Azad","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1172\/JCI131041","article-title":"Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer","volume":"130","author":"Beltran","year":"2020","journal-title":"J. Clin. Investigation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1158\/1078-0432.CCR-21-3762","article-title":"Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis","volume":"28","author":"Berchuck","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1200\/JCO.2023.41.6_suppl.221","article-title":"Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): incidence and natural history","volume":"41","author":"Bernard-Tessier","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/1078-0432.CCR-25-2121","article-title":"Liquid biopsy identifies taxane resistance and clonal selection in castration-resistant prostate cancer","volume":"28","author":"Brighi","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2174\/138920209787581307","article-title":"The role of androgen receptor mutations in prostate cancer progression","volume":"10","author":"Brooke","year":"2009","journal-title":"Curr. Genomics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41568-025-00795-x","article-title":"Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection","volume":"25","author":"Bruhm","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40258-025-00970-z","article-title":"The health economics of genomic technologies: a growing evidence base on value","volume":"23","author":"Buchanan","year":"2025","journal-title":"Appl. Health Econ. Health Policy"},{"key":"B16","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.eururo.2020.12.037","article-title":"Quantitative and qualitative analysis of blood-based liquid biopsies to inform clinical decision-making in prostate cancer","volume":"79","author":"Casanova-Salas","year":"2021","journal-title":"Eur. Urol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"11049","DOI":"10.3390\/ijms262211049","article-title":"Circulating tumor DNA as a biomarker for precision medicine in prostate cancer: a systematic review","volume":"26","author":"Chanhih","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40246-019-0220-8","article-title":"Next-generation sequencing in liquid biopsy: cancer screening and early detection","volume":"13","author":"Chen","year":"2019","journal-title":"Hum. Genomics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1158\/1078-0432.CCR-22-0931","article-title":"Detection of BRCA1, BRCA2, and ATM alterations in matched tumor tissue and circulating tumor DNA in patients with prostate cancer screened in PROfound","volume":"29","author":"Chi","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/annonc\/mdx155","article-title":"Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study","volume":"28","author":"Conteduca","year":"2017","journal-title":"Ann. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"oyaf107","DOI":"10.1093\/oncolo\/oyaf107","article-title":"Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer","volume":"30","author":"Conteduca","year":"2025","journal-title":"Oncologist"},{"key":"B22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","article-title":"Genome-wide cell-free DNA fragmentation in patients with cancer","volume":"570","author":"Cristiano","year":"2019","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.euros.2023.08.007","article-title":"Circulating tumour DNA biomarkers associated with outcomes in metastatic prostate cancer treated with Lutetium-177-PSMA-617","volume":"57","author":"Crumbaker","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"oyaf204","DOI":"10.1093\/oncolo\/oyaf204","article-title":"Circulating tumor DNA detection in cancer: a comprehensive overview of current detection methods and prospects","volume":"30","author":"de Abreu","year":"2025","journal-title":"Oncologist"},{"key":"B25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2025.43.5_suppl.16","article-title":"Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of 177 Lu-PSMA-617","volume":"43","author":"De Bono","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/s41416-021-01508-5","article-title":"Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a phase 2 trial","volume":"125","author":"De Giorgi","year":"2021","journal-title":"Br. J. Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1107\/S2053230X23002224","article-title":"A partially open conformation of an androgen receptor ligand-binding domain with drug-resistance mutations","volume":"79","author":"Doamekpor","year":"2023","journal-title":"Acta Crystallogr. F. Struct. Biol. Commun."},{"key":"B28","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/B978-0-12-824302-2.00009-6","article-title":"Circulating cancer biomarkers: current status and future prospects","volume-title":"Cancer Biomarkers","author":"Duffy","year":"2022"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","article-title":"Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer","volume":"15","author":"Fonseca","year":"2024","journal-title":"Nat. Commun."},{"key":"B30","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1158\/2159-8290.CD-23-0754","article-title":"Noninvasive detection of neuroendocrine prostate cancer through targeted cell-free DNA methylation","volume":"14","author":"Franceschini","year":"2024","journal-title":"Cancer Discov."},{"key":"B31","doi-asserted-by":"publisher","first-page":"EVIDe2300298","DOI":"10.1056\/EVIDe2300298","article-title":"Targeting androgen receptor mutations in metastatic castration-resistant prostate cancer with a novel androgen biosynthesis inhibitor","volume":"3","author":"Gao","year":"2023","journal-title":"NEJM Evid."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","article-title":"Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition","volume":"7","author":"Goodall","year":"2017","journal-title":"Cancer Discov."},{"key":"B33","doi-asserted-by":"publisher","first-page":"8062","DOI":"10.3390\/ijms21218062","article-title":"Putative origins of cell-free DNA in humans: a review of active and passive nucleic acid release mechanisms","volume":"21","author":"Grabuschnig","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1007\/s00259-021-05424-x","article-title":"Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging","volume":"48","author":"Gr\u00fcnig","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B35","doi-asserted-by":"publisher","first-page":"769","DOI":"10.5534\/wjmh.220200","article-title":"Systemic therapies for metastatic castration-resistant prostate cancer: an updated review","volume":"41","author":"Hatano","year":"2023","journal-title":"World J. Mens. Health"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/ph15101292","article-title":"[177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer","volume":"15","author":"Hennrich","year":"2022","journal-title":"Pharmaceuticals"},{"key":"B37","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1146\/annurev-med-100223-090016","article-title":"Circulating tumor DNA: a pan-cancer biomarker in solid tumors with prognostic and predictive value","volume":"76","author":"Hitchen","year":"2025","journal-title":"Annu. Rev. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","article-title":"The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis","volume":"63","author":"H\u00f6vels","year":"2008","journal-title":"Clin. Radiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/clinchem\/hvab176","article-title":"Circulating cell-free DNA yield and circulating-tumor DNA quantity from liquid biopsies of 12 139 cancer patients","volume":"67","author":"Huang","year":"2021","journal-title":"Clin. Chem."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e2200261","DOI":"10.1200\/PO.22.00261","article-title":"Tumor fraction correlates with detection of actionable variants across > 23,000 circulating tumor DNA samples","volume":"6","author":"Husain","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic \u2014 implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1191311","DOI":"10.3389\/fendo.2023.1191311","article-title":"Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution","volume":"14","author":"Imamura","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrurol.2018.9","article-title":"Clinical implications of PTEN loss in prostate cancer","volume":"15","author":"Jamaspishvili","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1111\/cas.15473","article-title":"Influence of response to prior docetaxel on sensitivity to cabazitaxel in prostate cancer patients with PTEN alterations","volume":"113","author":"Kamisawa","year":"2022","journal-title":"Cancer Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"key":"B48","doi-asserted-by":"publisher","first-page":"9530","DOI":"10.1073\/pnas.1105422108","article-title":"Detection and quantification of rare mutations with massively parallel sequencing","volume":"108","author":"Kinde","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"83","DOI":"10.21037\/tau.2017.12.24","article-title":"Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices","volume":"7","author":"Kinsella","year":"2018","journal-title":"Transl. Androl. Urol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"10648","DOI":"10.1038\/s41467-024-54847-1","article-title":"AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients","volume":"15","author":"Knutson","year":"2024","journal-title":"Nat. Commun."},{"key":"B51","doi-asserted-by":"publisher","first-page":"102728","DOI":"10.1016\/j.ebiom.2020.102728","article-title":"Clinical and genomic insights into circulating tumor DNA-Based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer","volume":"54","author":"Kohli","year":"2020","journal-title":"EBioMedicine"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.3390\/cancers17152589","article-title":"Circulating tumor DNA in prostate cancer: a dual perspective on early detection and advanced disease management","volume":"17","author":"Kopytov","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"273","DOI":"10.48083\/RFSH8912","article-title":"Utility and clinical application of circulating tumor DNA (ctDNA) in advanced prostate cancer","volume":"4","author":"Kostos","year":"2023","journal-title":"Soci\u00e9t\u00e9 Int. d\u2019Urologie J."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/15384047.2019.1598759","article-title":"Life and death of circulating cell-free DNA","volume":"20","author":"Kustanovich","year":"2019","journal-title":"Cancer Biol. Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fonc.2022.1054497","article-title":"Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: opportunities for integration and pitfalls to interpretation","volume":"10","author":"Kwan","year":"2022","journal-title":"Front. Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1038\/s41591-025-03704-9","article-title":"Lutetium-177\u2013PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial","volume":"31","author":"Kwan","year":"2025","journal-title":"Nat. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.1002\/mco2.766","article-title":"Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges","volume":"5","author":"Li","year":"2024","journal-title":"MedComm (Beijing)."},{"key":"B58","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1200\/JCO.2025.43.5_suppl.214","article-title":"The prognostic significance of circulating tumor DNA in prostate cancer: a systematic review and meta-analysis","volume":"43","author":"Liu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fonc.2021.599602","article-title":"The prognostic value of plasma cell-free DNA concentration in the prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"110330","DOI":"10.1016\/j.isci.2024.110330","article-title":"Prostate cancer detection through unbiased capture of methylated cell-free DNA","volume":"27","author":"Lleshi","year":"2024","journal-title":"iScience"},{"key":"B61","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.eururo.2022.09.010","article-title":"Emergence of BRCA reversion mutations in patients with metastatic castration-resistant prostate cancer after treatment with rucaparib","volume":"83","author":"Loehr","year":"2023","journal-title":"Eur. Urol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e240274","DOI":"10.1530\/ERC-24-0274","article-title":"Systems-level liquid biopsy in advanced prostate cancer","volume":"32","author":"Lyma","year":"2025","journal-title":"Endocr. Relat. Cancer"},{"key":"B63","first-page":"241","article-title":"Les acides nucl\u00e9iques du plasma sanguin chez l\u2019homme","volume":"142","author":"Mandel","year":"1948","journal-title":"C R. Seances Soc. Biol. Fil."},{"key":"B64","doi-asserted-by":"publisher","first-page":"S803","DOI":"10.21037\/tcr.2016.10.58","article-title":"Emerging mutations and functional changes of androgen receptor associated with treatment resistance in prostate cancer","volume":"5","author":"Martignano","year":"2016","journal-title":"Transl. Cancer Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann. Oncol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.3390\/cancers13133373","article-title":"Prostate cancer liquid biopsy biomarkers\u2019 clinical utility in diagnosis and prognosis","volume":"13","author":"Matuszczak","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B68","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13073-018-0595-5","article-title":"Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis","volume":"10","author":"Mayrhofer","year":"2018","journal-title":"Genome Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.eururo.2018.02.013","article-title":"Plasma cell-free DNA concentration and outcomes from taxane therapy in metastatic castration-resistant prostate cancer from two phase III trials (FIRSTANA and PROSELICA)","volume":"74","author":"Mehra","year":"2018","journal-title":"Eur. Urol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/14737159.2019.1684265","article-title":"An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer","volume":"20","author":"Mollica","year":"2020","journal-title":"Expert Rev. Mol. Diagn"},{"key":"B71","doi-asserted-by":"publisher","first-page":"eaat4921","DOI":"10.1126\/scitranslmed.aat4921","article-title":"Enhanced detection of circulating tumor DNA by fragment size analysis","volume":"10","author":"Mouliere","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e2400224","DOI":"10.1200\/CCI-24-00224","article-title":"Computational modeling for circulating cell-free DNA in clinical oncology","volume":"9","author":"Nguyen","year":"2025","journal-title":"JCO Clin. Cancer Inf."},{"key":"B74","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40644-021-00404-8","article-title":"Intra-patient comparison of physiologic 68Ga-PSMA-11 and 18F-DCFPyL PET\/CT uptake in ganglia in prostate cancer patients: a pictorial essay","volume":"21","author":"Osman","year":"2021","journal-title":"Cancer Imaging"},{"key":"B75","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41416-019-0716-y","article-title":"Hypoxia differently modulates the release of mitochondrial and nuclear DNA","volume":"122","author":"Otandault","year":"2020","journal-title":"Br. J. Cancer"},{"key":"B76","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jtho.2021.01.1616","article-title":"Biomarker discovery and validation: statistical considerations","volume":"16","author":"Ou","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"djag174","DOI":"10.1093\/jnci\/djag174","article-title":"Critical appraisal: prognostic versus predictive surrogate markers in oncology","volume":"2","author":"Pabani","year":"2026","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"B78","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.euf.2016.06.018","article-title":"Rationale for modernising imaging in advanced prostate cancer","volume":"3","author":"Padhani","year":"2017","journal-title":"Eur. Urol. Focus"},{"key":"B79","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1590\/0100-3984.2023.0003","article-title":"Musculoskeletal pitfalls in 68Ga-PSMA PET\/CT","volume":"56","author":"Pontes","year":"2023","journal-title":"Radiol. Bras."},{"key":"B80","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/14737159.2018.1400384","article-title":"Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective","volume":"18","author":"Postel","year":"2018","journal-title":"Expert Rev. Mol. Diagn"},{"key":"B81","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2147\/RRU.S388265","article-title":"Androgen receptor signalling in prostate cancer: mechanisms of resistance to endocrine therapies","volume":"17","author":"Quistini","year":"2025","journal-title":"Res. Rep. Urol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/MOU.0000000000001312","article-title":"Treatment of biochemical recurrence after primary therapy with curative intent","volume":"35","author":"Roessler","year":"2025","journal-title":"Curr. Opin. Urol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.euo.2024.08.006","article-title":"Liquid biopsy in progressing prostate cancer patients starting docetaxel with or without enzalutamide: a biomarker study of the PRESIDE phase 3b trial","volume":"8","author":"Ruiz-Vico","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.2967\/jnumed.123.266167","article-title":"Prediction of resistance to 177 Lu-PSMA therapy by assessment of baseline circulating tumor DNA biomarkers","volume":"64","author":"Sartor","year":"2023","journal-title":"J. Nucl. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nrc3066","article-title":"Cell-free nucleic acids as biomarkers in cancer patients","volume":"11","author":"Schwarzenbach","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"B87","first-page":"1496","article-title":"Functional analysis of 44 mutant androgen receptors from human prostate Cancer1","volume":"62","author":"Shi","year":"2002","journal-title":"Cancer Res."},{"key":"B88","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1530\/ERC-22-0140","article-title":"Androgen receptor mutations for precision medicine in prostate cancer","volume":"29","author":"Shiota","year":"2022","journal-title":"Endocr. Relat. Cancer"},{"key":"B89","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"B90","doi-asserted-by":"publisher","first-page":"926585","DOI":"10.3389\/fendo.2022.926585","article-title":"The role of epigenetic change in therapy-induced neuroendocrine prostate cancer lineage plasticity","volume":"13","author":"Storck","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B91","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B92","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1038\/s41598-022-08520-6","article-title":"Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer","volume":"12","author":"Tan","year":"2022","journal-title":"Sci. Rep."},{"key":"B93","doi-asserted-by":"publisher","first-page":"102595","DOI":"10.1016\/j.ctrv.2023.102595","article-title":"Strategies for improving detection of circulating tumor DNA using next generation sequencing","volume":"119","author":"T\u00e9bar-Mart\u00ednez","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3390\/cancers18111702","article-title":"Circulating tumor DNA as emerging predictive and prognostic biomarker in prostate cancer","volume":"18","author":"Thapa","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B95","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1200\/PO.20.00084","article-title":"A systematic review and meta-analysis on the predictive value of cell-free DNA\u2013based androgen receptor copy number gain in patients with castration-resistant prostate cancer","volume":"4","author":"Tolmeijer","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1158\/1078-0432.CCR-22-2998","article-title":"Early On-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer","volume":"29","author":"Tolmeijer","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.3892\/ijo.2014.2601","article-title":"Targeting the PI3K\/Akt pathway in prostate cancer: challenges and opportunities","volume":"45","author":"Toren","year":"2014","journal-title":"Int. J. Oncol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1002\/pros.24618","article-title":"Impact of androgen receptor alterations on cell\u2010free DNA genomic profiling on survival outcomes in metastatic castration\u2010resistant prostate cancer","volume":"83","author":"Tripathi","year":"2023","journal-title":"Prostate"},{"key":"B99","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-20-4805","article-title":"Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms","volume":"27","author":"Tukachinsky","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B100","article-title":"Use of circulating tumor deoxyribonucleic acid for early-stage solid tumor drug development","year":"2024","journal-title":"Guid. Industry"},{"key":"B101","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.euros.2023.05.008","article-title":"AR and PI3K genomic profiling of cell-free DNA can identify poor responders to Lutetium-177-PSMA among patients with metastatic castration-resistant prostate cancer","volume":"53","author":"Vanwelkenhuyzen","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"B102","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00259-019-04529-8","article-title":"Influence of androgen deprivation therapy on PSMA expression and PSMA-Ligand PET imaging of prostate cancer patients","volume":"47","author":"Vaz","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B103","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/ng0495-401","article-title":"In vivo amplification of the androgen receptor gene and progression of human prostate cancer","volume":"9","author":"Visakorpi","year":"1995","journal-title":"Nat. Genet."},{"key":"B104","doi-asserted-by":"publisher","first-page":"e0237802","DOI":"10.1371\/journal.pone.0237802","article-title":"Clinical and analytical validation of FoundationOne liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin","volume":"15","author":"Woodhouse","year":"2020","journal-title":"PLoS One"},{"key":"B105","doi-asserted-by":"publisher","first-page":"777663","DOI":"10.3389\/fphar.2021.777663","article-title":"Evaluation of the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12864-016-3425-4","article-title":"Detecting very low allele fraction variants using targeted DNA sequencing and a novel molecular barcode-aware variant caller","volume":"18","author":"Xu","year":"2017","journal-title":"BMC Genomics"},{"key":"B107","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.12998\/wjcc.v10.i11.3461","article-title":"Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: a case report","volume":"10","author":"Yuan","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"B108","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1007\/s00210-023-02539-w","article-title":"PSMA-617 inhibits proliferation and potentiates the 177Lu-PSMA-617-induced death of human prostate cancer cells","volume":"396","author":"Zhao","year":"2023","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1158\/0008-5472.CAN-24-1943","article-title":"Longitudinal profiling of circulating tumor DNA reveals the evolutionary dynamics of metastatic prostate cancer during serial therapy","volume":"85","author":"Zhao","year":"2025","journal-title":"Cancer Res."},{"key":"B110","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3390\/biomedicines14010158","article-title":"Liquid biopsy in early screening of cancers: emerging technologies and new prospects","volume":"14","author":"Zhu","year":"2026","journal-title":"Biomedicines"}],"container-title":["Frontiers in Molecular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmmed.2026.1852641\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:13:18Z","timestamp":1785481998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmmed.2026.1852641\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":110,"alternative-id":["10.3389\/fmmed.2026.1852641"],"URL":"https:\/\/doi.org\/10.3389\/fmmed.2026.1852641","relation":{},"ISSN":["2674-0095"],"issn-type":[{"value":"2674-0095","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"1852641"}}